Can I take melatonin for my joint pain?

This is a clinical decision to make with your GP. Melatonin's TGA-approved indications in Australia relate to sleep disorders, not pain management. Using it for pain is off-label prescribing — legal in Australia and sometimes clinically appropriate, but requiring your doctor to weigh it against your full medical history, current medicines, and existing pain management plan. It should not replace established first-line approaches such as physiotherapy, exercise, and prescribed pain medicines.

Who might most benefit from melatonin for pain, based on the evidence?

The meta-analysis found the strongest signal in people with chronic musculoskeletal conditions where pain coincided with significant sleep disruption. If you have both persistent joint or muscle pain and substantial sleep difficulties, the overlap may be worth raising with your GP — since treating sleep disruption through melatonin might reduce pain indirectly, and some direct analgesic effect appears possible in this population. This is a conversation to have, not a self-prescribing recommendation.

Melatonin for chronic pain: what a 23-trial review actually found

What just happened

A meta-analysis summarising 23 clinical trials and more than 2,000 participants found that melatonin provides modest relief for chronic muscle and joint pain — reducing pain scores by approximately 9 points on a 100-point scale.

The findings were written up for The Conversation by Dipa Kamdar, a Senior Lecturer in Pharmacy Practice at Kingston University and the researcher who conducted the review. The meta-analysis examined melatonin’s effects on conditions including fibromyalgia, osteoarthritis, and other chronic musculoskeletal conditions, as well as post-surgical pain.

The finding is clinically interesting for a specific reason: melatonin is not a conventional analgesic. It is a hormone the pineal gland produces in response to darkness, primarily known for regulating sleep-wake cycles. The fact that a review of this scale is finding a consistent signal in chronic pain suggests the hormone may have analgesic properties beyond sleep — a finding that deserves careful unpacking before it becomes self-prescribing advice.

The both-and

What the numbers actually mean

A 9-point reduction on a 100-point pain scale is real, but it requires context. In pain trial methodology, 10 points is often used as the threshold for “minimal clinically important difference” — the level at which individual patients would reliably notice benefit. The melatonin effect sits just at or below this threshold, depending on the condition studied.

Placebo responses in chronic pain trials typically reach 10–15 points. The net analgesic benefit of melatonin above placebo depends on which comparison each individual trial used — and the meta-analysis, by pooling across diverse conditions and designs, cannot give a precise answer to that question.

The signal is most consistent in conditions where chronic pain overlaps with sleep disruption. This makes biological sense: poor sleep amplifies pain sensitivity through a process called central sensitisation, where the nervous system becomes progressively more reactive to pain signals. Melatonin improving sleep architecture could reduce pain indirectly, independently of any direct analgesic mechanism. The researcher also proposes direct pathways — dampening pain signals in the spinal cord, reducing neuroinflammation, and antioxidant effects — but these remain theoretical from the available human trial data.

Post-surgical pain told a different story: melatonin’s effect was negligible (2.5 points on the same scale). This suggests it is not a general-purpose pain reliever but something more specific to the chronic, sleep-adjacent pain picture.

Dosing remains unresolved. Trials used doses ranging from 1mg to 10mg, with no clear optimal dose established. Reported side effects included daytime sleepiness, dizziness, and headache — relevant considerations for people who drive, work, or care for others.

The Australian regulatory picture

In Australia, melatonin’s TGA-approved indications relate to sleep disorders. Modified-release melatonin is PBS-listed for primary insomnia in adults aged 55 and over. For pain management specifically — at any age — melatonin is not a TGA-registered treatment in Australia.

That does not make it inaccessible, but it does shape how to access it responsibly. Off-label prescribing is legal in Australia when a prescriber considers it clinically appropriate for an individual patient. But it is the prescriber’s decision — not something to arrive at through self-medication or over-the-counter purchase from supplement retailers, which operate outside the quality and dosing standards of registered medicines.

For women in perimenopause, there is a specific angle worth noting. Menopausal joint pain — sometimes called arthralgia — is a recognised and frequently under-discussed symptom of the oestrogen changes during the transition years, affecting the knees, hips, hands, and spine. Whether melatonin’s apparent musculoskeletal benefit in this meta-analysis applies to menopausal arthralgia specifically is unknown; the trials did not stratify by menopausal status.

Why this story still matters

Pain Australia estimates that approximately 3.6 million Australians live with chronic pain, and treatment options — particularly for people with moderate, persistent pain that does not warrant opioid prescribing but is inadequately managed by paracetamol or anti-inflammatories — remain limited. A consistent signal across 2,000+ participants suggesting a low-risk, sleep-adjacent agent may have genuine musculoskeletal benefit is worth tracking, even if the current evidence does not yet support routine use.

The researcher’s recommendation frames this appropriately: melatonin as an add-on alongside physiotherapy and exercise, not as a standalone or replacement for established pain management. Treating sleep as part of chronic pain care is already considered best practice; this meta-analysis gives that approach a more specific biological rationale.

My two cents

The evidence is real but modest. A 9-point reduction in a 23-trial review is meaningful enough not to dismiss, and insufficient on its own to turn into a treatment recommendation.

What it points to practically: if you have chronic joint or muscle pain that is significantly worsening your sleep — or if sleep disruption appears to be amplifying your pain — that overlap is worth naming at a GP appointment. Not as “can I have melatonin for pain,” but as a conversation about how sleep and pain are interacting and what options exist for addressing both.

First-line approaches for chronic musculoskeletal pain — exercise, physiotherapy, anti-inflammatory medicines where appropriate — remain better evidenced than melatonin for pain specifically, and those foundations should not be displaced by an off-label option whose pain-specific benefit is, so far, modest.

Verdict: maybe — the signal is genuine, but this is a conversation to have with your GP, not an action to take alone.

Sources cited

Kamdar D. “Melatonin may help ease chronic muscle and joint pain, new study suggests.” The Conversation, 16 July 2026. https://theconversation.com/melatonin-may-help-ease-chronic-muscle-and-joint-pain-new-study-suggests-286792
Pain Australia. About Pain. https://www.painaustralia.org.au/about-pain
Therapeutic Goods Administration (TGA). https://www.tga.gov.au